Oxandrin: profile and news

Savient Reports Results for First Quarter 2006  May 11, 2006
Net product sales were $18.9 million compared to $20.8 million in 2005, a decrease of 9%, attributable to the decrease in Oxandrin(R) sales and the sale of ... - Finanzen.net,

Savient Receives FDA Final Approval for Puricase (PEG-uricase) ...  May 3, 2006
...initial focus inrheumatology. Savient markets its product Oxandrin(R) (oxandrolone,USP) in the United States. The Company's subsidiary ... - Finanzen.net,

Cytogen and Savient Finalize Exclusive Distribution Agreement for ...  Apr 24, 2006
...initial focus in rheumatology. Savient markets its product Oxandrin® (oxandrolone, USP) in the United States. The Company's subsidiary ... - Yahoo! News (press release)